( SAN DIEGO--(BUSINESS WIRE)--Mar 29 200...)ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research,Health

SAN DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present at the 2007 International Congress on Schizophrenia Research, held from March 28 through April 1, 2007, in Colorado Springs, Colorado. Presentations will cover ACADIA's two schizophrenia programs and will include previously announced top-line clinical data from the recently completed ACP-103 Phase II schizophrenia co-therapy trial, as well as preclinical and top-line clinical data on ACP-104 for the treatment of schizophrenia.

ACP-103: Top-Line Data from Phase II Schizophrenia Co-Therapy Trial

Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA, will make an oral presentation on April 1 titled "ACP-103, a 5-HT2A Inverse Agonist in Schizophrenia and Parkinson's Disease Psychosis." This presentation will include previously announced top-line results from the recently completed ACP-103 Phase II schizophrenia co-therapy trial, which highlighted several advantages of co-therapy with ACP-103, including enhanced efficacy, a faster onset of antipsychotic action, and an improved side effect profile. Dr. Hacksell also will present new data from this study showing that patients in the co-therapy arm combining ACP-103 with risperidone (2 mg) had significantly lower prolactin levels after 42 days of treatment compared to patients in the risperidone (6 mg) plus placebo arm (p=0.0001). The condition of elevated prolactin is a commonly observed side effect of antipsychotic therapy and may adversely affect menstrual and sexual function as well as bone formation.

ACP-104: Top-Line Data From Single Ascending-Dose and Multiple Ascending-Dose Studies

Professor Carol Tamminga, M.D., from the University of Texas Sout
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
3. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
4. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
5. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
10. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
11. New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia